CN104824511A - Prebiotics composition - Google Patents
Prebiotics composition Download PDFInfo
- Publication number
- CN104824511A CN104824511A CN201510263942.3A CN201510263942A CN104824511A CN 104824511 A CN104824511 A CN 104824511A CN 201510263942 A CN201510263942 A CN 201510263942A CN 104824511 A CN104824511 A CN 104824511A
- Authority
- CN
- China
- Prior art keywords
- mouse
- preparation
- prebiotics
- cell
- glucosamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 7
- 235000013402 health food Nutrition 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 9
- 230000036039 immunity Effects 0.000 abstract description 7
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 abstract description 6
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 abstract description 6
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 abstract description 6
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 abstract description 5
- 229920001100 Polydextrose Polymers 0.000 abstract description 3
- 239000001259 polydextrose Substances 0.000 abstract description 3
- 229940035035 polydextrose Drugs 0.000 abstract description 3
- 235000013856 polydextrose Nutrition 0.000 abstract description 3
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 abstract 1
- 229940107187 fructooligosaccharide Drugs 0.000 abstract 1
- 229960002849 glucosamine sulfate Drugs 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 25
- 230000000694 effects Effects 0.000 description 22
- 239000007788 liquid Substances 0.000 description 19
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 17
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 17
- 229960002442 glucosamine Drugs 0.000 description 17
- 210000000952 spleen Anatomy 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 210000000936 intestine Anatomy 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000000242 pagocytic effect Effects 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 description 7
- 210000001188 articular cartilage Anatomy 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000005534 hematocrit Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000003321 cartilage cell Anatomy 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010072970 Meniscus injury Diseases 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000976 ink Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000004417 patella Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CHVZQMAANSUXJU-JJKGCWMISA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide;hydrochloride Chemical compound Cl.NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CHVZQMAANSUXJU-JJKGCWMISA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 101000672034 Bacillus sp. (strain GL1) Unsaturated glucuronyl hydrolase Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 108010066657 azoreductase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000003846 cartilage breakdown Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000011475 lollipops Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 231100000586 procarcinogen Toxicity 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- -1 pulvis Substances 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000019722 synbiotics Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention relates to a prebiotics composition which contains fructo-oligosaccharide, stachyose, xylooligosaccharide, polydextrose and glucosamine sulfate. The composition can be prepared into foods or health-care foods suitable for being taken. Experiments confirm that the prebiotics composition plays the role of enhancing the immunity.
Description
Technical field:
The present invention relates to a kind of prebiotic compositions favourable to proliferation of probiotics, particularly containing FOS, stachyose, xylo-oligosaccharide, the composition of polydextrose and Glucosamine.
Background technology:
Prebiotics is a kind of dietary supplements, by optionally stimulating the growth of one or more bacteriums with active, and produces wholesome effect to host, thus improves host health.The most basic prebiotics is carbohydrate, but the non-carbohydrate material being used as prebiotics is not got rid of in definition.In theory, any can minimizing is harmful to bacterial classification now, and the antibiotic being of value to sanatory bacterial classification or activity can be called prebiotics.Prebiotics, when by alimentary canal, major part not by human consumption, but is absorbed by gut flora.The most important thing is, its flora (probio) that just propagation is useful to human body, instead of propagation has the harmful bacteria of potential pathogenic or corrupt activity to human body.
Prebiotics provides " food " to probio, can be decomposed and absorb, promote beneficial bacteria growth and breeding by beneficial bacteria in enteron aisle.Everybody the Oilgosaccharkdes be familiar be exactly the prebiotics promoting bifidobacterium growth in intestines.Prebiotics mainly comprises various oligosaccharide kind material (Oligosaccharides) or claims compound sugar (being made up of 2 ~ 10 molecule monose).More generally method is functional oligose.If isomalto-oligosaccharide is exactly a kind of prebiotics.
Known effect of prebiotics is as follows:
Alleviate constipation symptom:
This effect is well confirmed as effect of dietary fibre.A lot of prebiotics is the carbohydrate fermented in large intestine.Produce intestines gas by fermentation increase intestines volume thus shorten the residence time of digest in intestines.Constipation is oversize and cause by digest residence time in intestines.Short naturally to contribute in elapsed time, resists constipation.
In addition, many carbohydrate can increase the moisture of intestines, and the secretion of acid can stimulate enterocinesia.These can reduce the time of digest through intestines equally.
Produce the change of metabolism based on to new instead of pass through to stimulate certain bacterium, best effect is obtained by the carbohydrate mixture comprising dietary fiber.
Reduce intestines pH value:
This effect comes since Rumen protein fermentation (generating ammonia, high pH) is to the change of more carbohydrate fermentation (generating acid) owing to newly producing metabolism.The feature of some intestines problems as segmental meeting enteritis and IBS (acute intestinal syndrome) is all have too high intestines pH value.Reduce pH thus the generation of (not cure) these diseases can be reduced.This is of value to patient.
Conditioning bacterial equilibrium:
Prebiotics can help intestines through antibiotic, suffers from diarrhoea, and recovers intestinal bacterium balance after the interference of pressure or other medicines (non-antibiotic class).Integrated compensation is made by the optionally stimulation to certain specific flora.May occur on a variety of different flora.This stimulation can be directly (being grown on prebiotics by the bacterium selected) or indirectly (material that the release of some bacteriums is useful to other bacterial growth)
In this case, selective stimulating and metabolic change all play a role.
Immune-enhancing effect:
Prebiotics itself to immune system without any effect.But by changing intestines bacterium colony thus may immune system being affected.This stimulation can be useful or unhelpful, and beneficial effect refers to that immune system is activated to resist pathogenic bacteria.Unhelpful effect says owing to stimulating the allergic reaction that may cause.
Edible prebiotic oligosaccharide also effectively can reduce putrefactivebacteria generation p glycuronidase, azo reductase, nitroreductase etc. by promoting Bifidobacterium propagation can become carcinogenic enzymatic activity by catalysis procarcinogen.Compound sugar also can combine and conduct ~ kind of immunologic adjuvant with certain toxin, virus and bacterium surface, can slow down the absorption to antigen, tiring and human body fluid immunity of enhancement antigen.
Promote infantile health:
The intestines bacterium colony of less than four years old children is very unstable.Many mouths enter pathogenic bacteria can disturb microbe colony.The material can stablizing bacterium colony can be considered to prebiotics.Some researchs point out that some business-like monose can change bacterium colony and reduces pH value and play by stabilizing effect.
Glucosamine (C6H13NO5), also known as gucosamine, aminoglucose or aminoglucose, is the compound after a hydroxyl of glucose is replaced by amino.Glucosamine is the important as precursors in protein or lipid glycosylation.Clinical conventional Glucosamine Sulphate or aminoglucose hydrochloride.
Glucosamine is one of the abundantest monose of nature content.Industrial usual employing hydrolysis shellfish ectoskeleton produces Glucosamine.Glucosamine is often used in the meals supplemental treatment of osteoarthritis, and Glucosamine is the material of synthesis in human body, and being the important nutrient forming cartilage cell, is the natural tissues composition of healthy articular cartilage.With advancing age, the shortage of the Glucosamine in human body is more and more serious, and articular cartilage is constantly degenerated and worn and torn.The U.S., Europe and Japanese a large amount of medical researches show: Glucosamine can help repair and safeguard cartilage, and can stimulate the growth of cartilage cell.
The Main Function of Glucosamine is as follows:
1, DA
Glucosamine, mainly through repairing articular cartilage, expedites the emergence of knuckle synovia, makes, between articular surface, rigid friction no longer occurs, no longer there is the symptoms such as pain, swelling, bony crepitus, and by the reparation to articular cartilage, make joint space recover normal, function of joint is thoroughly recovered.
2, osteoproliferation
Exogenous absorption Glucosamine, Glucosamine content in joint is restored balance state, stimulate cartilage cell's synthetic proteins polysaccharide and collagenous fibres, generate cartilage matrix, repair damaged cartilage, articular cartilage self repair ability is improved, by Glucosamine repairing articular cartilage, expedites the emergence of knuckle synovia, essence therapeutic action is played to osteoproliferation arthritis (osteoarthritis).
3, meniscus injury
Glucosamine can repair the meniscus of damage, repairs the articular surface Cartilage breakdown of meniscus injury secondary simultaneously, fundamentally repairs joint injury.Glucosamine can remove injurious factor simultaneously, suppresses and eliminates the reaction of synovium of joint inflammatory.
4, kneecap, malacosis
Supplement Glucosamine exogenously, the articular cartilage between kneecap and femur can be repaired.
Existing prebiotics kind is more, and some adds Chinese medicine or Western medicine, and some and probio are share, and the prebiotics product containing FOS and stachyose and associated additives as described in existing patented technology has:
| 201210470492.1 | A kind of preparation method of the bifid bacterium microcapsule containing prebiotics |
| 201080007451.8 | The proton pump that comprises being used for the treatment of gastric ulcer and duodenal ulcer presses down |
| The pharmaceutical composition of preparation and prebiotics | |
| 200810302182.2 | Synbiotics medicament composition |
| 201310001903.7 | For the probiotics fermention composition of prevention and therapy constipation |
| 201380042948.7 | Be used for the treatment of the pharmaceutical composition of GERD |
| 201010520691.X | A kind of honeysuckle liquid compound formulation of applicable infants |
| 201410330755.8 | For composition and the preparation of gynecological infection |
The present invention is on the basis of prebiotics part, work out a kind of new prebiotic compositions, appropriate Glucosamine Sulphate is joined containing FOS, stachyose, xylo-oligosaccharide, be prepared into a kind of prebiotic compositions in the prebiotics of polydextrose, through screening the dosage of each component, the prebiotic compositions of unexpected discovery proportioning of the present invention has the effect of good collaborative increase immunity.
Summary of the invention;
The invention provides a kind of prebiotic compositions, described composition, the weight proportion of each component is as follows:
Preferably, described composition, the weight proportion of each component is as follows:
In above composition, described part is weight portion, can with g, kg or mg etc. for unit.
Above composition is prior art, can buy from the market and obtain, and belongs to food or health food category.
The present invention comprises the preparation method of the present composition further, and described method comprises the step component of above-mentioned weight proportion mixed.
Prebiotic compositions of the present invention can as a kind of active component of immunopotentiator, and described immunopotentiator can comprise any one and be applicable to oral dosage form, as tablet, capsule, granule, oral liquid, pulvis, pills etc., also can be prepared into applicable edible food form, as sugar, biscuit, dairy produce, ice lolly, bread, jam etc.
The preparation of said products can adopt conventional manufacturing techniques, as using prebiotic compositions of the present invention as active component, adds auxiliary material if desired, as sweetener, flavouring, the galenic pharmacy routine techniques such as excipient is prepared into tablet, capsule etc., or be prepared into food with food routine techniques.
Prebiotic compositions of the present invention, comprises two-part composition, and a part is prebiotic component, i.e. FOS, stachyose, xylo-oligosaccharide, the part of poly-grape, another part is Glucosamine Sulphate part, the present invention is using Glucosamine Sulphate as keeping fit the use of key bone component, and as prebiotics replenishers, but the present invention finds unexpectedly, these two parts share has the collaborative effect improving immunity, and regarding assay is as follows:
Develop immunitypty function test
Sample:
Of the present invention group: prebiotic compositions 100g of the present invention in Example 1, is mixed with 400ml liquid, gastric infusion.
Prebiotics part group: FOS 90g, stachyose 1g, xylo-oligosaccharide 3g, poly-grape 2g is mixed with 400ml liquid, gastric infusion.
Glucosamine Sulphate group: Glucosamine Sulphate 4g, is mixed with 400ml liquid, gastric infusion.
Animal used as test: mouse 200, male and female half and half, body weight 18 ~ 22g, cavy 100, male and female are more than half, body weight 300 ~ 350g,
Dosage choice and tested material give mode
Sample thief gives mouse stomach respectively respectively, and once a day, gavage volume is 0.2ml/10gbw, and negative control group gives equal-volume distilled water, continuous 30 days.
Test method
Above-mentioned tested material gives by body weight every day, continuous 30 days, in administration simultaneously, observes the state of animal every day,
Take weekly a weight of animals, and measure indices by the following method.
(1) internal organs/weight ratio pH-value determination pH: after mouse weights record, dislocation is put to death, and gets spleen and thymus gland, removes most manadesma, weigh.Calculate spleen/body weight ratio and thymus gland/body weight ratio.
(2) the mouse spleen lymphocyte transformation experiment (mtt assay) of ConA induction: experiment mice dislocation is put to death, immerse in 75% medicinal alcohol, asepticly get spleen, be placed in the aseptic little mortar filling Hank's liquid, rapidly spleen is ground, make splenocyte suspension, aseptic Hank ' s liquid is used to filter in test tube by cell permeable 6 layers of sterile gauze, 1000rpm, centrifugal 2 times of 10min, abandons supernatant and is upspring by cell, and it is resuspended containing the RPMI1640 complete culture solution of 10% calf serum to add 2mL, spleens cell number is measured, by cell number furnishing experiment desired concn with cell counter.Add in 24 well culture plates by the cell suspension point holes adjusting cell concentration, every hole 1mL, add 50 μ l ConA solution (being equivalent to 5 μ g/ml) wherein in a hole, (5%CO in incubator in contrast, is put in another hole
2, 37 DEG C) cultivate 72 hours.Cultivation terminates first 4 hours, every hole sucks supernatant 0.7mL gently, add 0.7mL not containing the RPMI1640 nutrient solution of calf serum and the MTT/RPMI1640 (5mg/ml) of 50 μ l, continue cultivation 4 hours, cultivate after terminating, every hole adds 1mL acid isopropyl alcohol, purple crystal is dissolved completely, and then moved into by this liquid in 96 hole ELISA Plates, packing 4 holes in each hole are as Duplicate Samples, colorimetric on ELIASA, result represents with the OD value at wavelength 570nm place.Lymphocytic multiplication capacity deducts by the OD value adding ConA hole the OD value not adding ConA hole and represents.
(3) delayed allergy (the sufficient sole of the foot thickens method): every mouse is through lumbar injection 2% (with normal saline) hematocrit SRBC suspension 0.2mL.After immunity 4d, with the left back sufficient sole of the foot thickness (background values) of kind of calliper, same position duplicate measurements three times, calculating mean value.Then at measuring point hypodermic injection 20% hematocrit SRBC, every mouse 20 μ L.After injection, 24h measures left back sufficient sole of the foot thickness again.Pedal swelling degree is represented by the difference of attacking the twice sufficient sole of the foot one-tenth-value thickness 1/10 in front and back.
(4) antibody-producting cell detects: cavy femoral artery (30) is taken a blood sample, isolate serum, it is mixed by 1:5 with hematocrit SRBC, place 30min, frequently shake, 2000rpm for 4 DEG C, 10min centrifuging and taking supernatant, packing ,-30 DEG C of preservations, the used time presses 1:10 dilution with SA buffer solution.Agarose distilled water is mixed with 1% solution, and water-bath is boiled, and makes it to melt completely, is applied on clean slide, for subsequent use in film releasing box after dry.Every mouse is through lumbar injection 2% (preparing with physiological salt liquid) hematocrit SRBC suspension 0.2mL.By immunity 5 days after mouse dislocation put to death, take out spleen, be placed on fill Hank ' s liquid little mortar in, grind, filtered in 10ml test tube by cell with 2 layers of gauze, 1000rpm, 10min are centrifugal, abandon supernatant, wash 1 time with Hank ' s liquid, splenocyte is suspended in 10mLHank ' s liquid for subsequent use.Agarose is mixed with 1% aqueous solution, water-bath is boiled, make it to melt completely, mix with equivalent double Hank ' s liquid, packing small test tube, often pipe 0.5mL, in pipe, add 10% (using SA buffer) hematocrit SRBC suspension 50 μ L, splenocyte suspension 10 μ L again, rapidly after mixing, be poured on agarose thin layer slide, after agar solidification, slide level being buckled is placed on horse, puts into 37 DEG C of incubators and hatches 1.5 hours, is then joined by complement in slide frame groove, after continuing to hatch 1.5 hours, counting hemolysis plaque number.Draw 20ul splenocyte suspension, add 10ml cell diluent, fully mix, counting spleens cell number.With plaque number/10
6splenocyte represents.
(5) mensuration (Hemagglutination Method) of serum hemolysin: mouse is through lumbar injection 2% hematocrit SRBC (with normal saline) suspension 0.2mL.Mouse after immune 4-5 days is extractd eyeball, gets whole blood in microcentrifugal tube, leave standstill 1h, 2000r/min, 10min centrifugal, collect serum.With physiological saline by serum doubling dilution, dilution for difference serum is placed in Microhemagglutination brassboard respectively, every hole 100 μ l, add the SRBC suspension of 100 μ l 0.5% (v/v) again, mixing, be loaded in moistening square position and add a cover, in 37 DEG C of incubation 3h, observe hemagglutination degree.
Result antibody product represents.In antibody horizontal=(S1+2S2+3S3nSn) formula 1,2,3n represents the index of two-fold dilution, S represents the rank of aggegation degree, and antibody product is about large, represents that serum antibody is higher.
(6) mouse carbonic clearance test: in the india ink 0.2ml of mouse tail vein injection dilution, treat that prepared Chinese ink injects, immediately timing.Respectively at 2,10 minutes, get blood 20 μ l from left side angular vein clump, and be added to 2mL Na
2cO
3in solution.With Na
2cO
3solution makes blank, with ultraviolet-uisible spectrophotometer at 600nm wavelength place densitometric value (OD).After mouse weights, cervical dislocation is put to death, and gets liver and spleen, removes most manadesma, weigh (g).Calculate phagocytic index.
(7) Turnover of Mouse Peritoneal Macrophages engulfs chicken red blood cells experiment (half intracorporal method): mouse peritoneal injects 20% chicken erythrocyte suspension 1ml, interval is after 30 minutes, inject Hank's liquid 2ml again, mouse is put to death with cervical dislocation, rub belly gently 30 times, fully to wash out peritoneal macrophage, then stomach wall is cut off an osculum, draw abdominal cavity washing lotion 0.5ml with syringe, drip on the slide being decorated with circle.Slide is put into the enamel box being lined with wet gauze, dislocation 37 DEG C of incubator incubations 30 minutes.Hatch after terminating and with Hank's liquid, non-attached cell is washed out rapidly, dry.In methanol solution, fix 5 minutes, Giemsa liquid dyes 20 minutes.Under oily mirror, 100 macrophages are counted to every mouse, engulf in record macrophage the macrophage numbers of chicken red blood cell and macrophage engulf the sum of chicken red blood cell.Be calculated as follows phagocytic index and phagocytic rate:
The macrophage of the sum/counting of chicken red blood cell is engulfed in phagocytic index=macrophage
Macrophage number × 100% of phagocytic rate (%)=the engulf macrophage number/counting of chicken red blood cell
(8) NK cytoactive detection (LDH method): test and target cell YAC-1 was carried out Secondary Culture in first 24 hours, before application, is 1 × 10 with the RPMI1640 complete culture solution adjustment cell concentration containing 10% calf serum
5individual/mL.Mouse cervical dislocation is put to death, and asepticly gets spleen, is placed in the aseptic little mortar filling Hank's liquid, is ground by spleen rapidly, makes splenocyte suspension, with the washing of Hank ' s liquid, and centrifugal 2 times of 1000rpm, 10min.Abandon supernatant to be upspring by sedimentation cell, it is resuspended containing the RPMI1640 complete culture solution of 10% calf serum to add 2mL, measures spleens cell number with cell counter.By cell number furnishing 5 × 10
6individual/ml, makes effect (splenocyte) target (YAC-1) cell than being 50:1.Get target cell and each 100 μ L of effector cell, add in U-shaped 96 porocyte culture plate; Target cell Spontaneous release hole adds target cell and each 100 μ L of nutrient solution, and the maximum release aperture of target cell adds target cell and each 100 μ L of 1%NP40; Above-mentionedly everyly all establish three parallel holes, 37 DEG C, 5%CO
2cultivate 4 hours in incubator.At the end of cultivation, by 96 porocyte culture plates with 1500rpm centrifugal 5 minutes, every hole was drawn supernatant 100 μ L and is put in 96 hole ELISA Plates, add LDH matrix liquid 100 μ L, room temperature reaction 3 minutes, then every hole adds the HCl solution 30 μ L cessation reaction of 1mol/L, surveys OD value at 490nm place with ELIASA.
NK cytoactive %=(reacting hole OD-Spontaneous release hole OD)/(maximum release aperture OD-Spontaneous release hole OD) × 100%
Experimental result
(1) to the observation of the weight of animals change, in table 1,2,3,4,5:
Table 1 develop immunitypty preparation is on the impact of immune I group Mouse Weight:
Table 2 develop immunitypty preparation is on the impact of immune II group Mouse Weight:
Table 3 develop immunitypty preparation is on the impact of immune III group Mouse Weight:
Table 4 develop immunitypty preparation is on the impact of immune IV group Mouse Weight:
Table 5 develop immunitypty preparation is on the impact of immune V group Mouse Weight:
From table 1-5, each dosage group experiment initial stage, experiment mid-term, experiment Mouse Weight in latter stage and the growth of experimental session Mouse Weight are compared with negative control group, there was no significant difference (P>0.05).
(2) must affect, in table 6 mouse thymus/weight ratio and spleen/weight ratio:
Table 6 develop immunitypty preparation is on the impact of mouse immune organ internal organs/weight ratio
From table 6: per os gives mouse each dosage group develop immunitypty preparation 30 days, without conspicuousness, (P>0.05) is affected to mouse spleen/body weight ratio and thymus gland/body weight ratio.
(3) develop immunitypty preparation is on the impact of mouse cell immunologic function, in table 7,8:
A: the impact that develop immunitypty preparation is tested mouse ConA induction of lymphocyte conversion capability, in table 7
Table 7 develop immunitypty preparation is to mouse lymphocyte conversion capability experimental result (lymphopoiesis ability)
From table 7: three groups, develop immunitypty preparation all can significantly improve mouse lymphocyte conversion capability, have significant difference with the mouse lymphocyte conversion capability of negative control group, wherein of the present invention group of effect is optimum, and has synergistic function.
B develop immunitypty preparation on the impact of mouse delayed allergy, in table 8:
Table 8 develop immunitypty preparation is on mouse delayed allergy (the sufficient sole of the foot thickens method) impact (sufficient sole of the foot thickness difference mm)
From table 8: the difference of three groups of foot sole of the foot thickness is significantly higher than the difference of negative control group foot sole of the foot thickness, and wherein of the present invention group of effect is optimum, and has synergistic function.
Cellular immune function assay result: mouse lymphocyte transformation experiment result is positive; Delayed allergy (the sufficient sole of the foot thickens method) result is for positive.Cellular immune function assay result is positive.
(4) develop immunitypty preparation is on the impact of humoral immune function, in table 9,10:
A develop immunitypty preparation on the impact of mouse antibodies cellulation, in table 9:
Table 9 develop immunitypty preparation is on mouse antibodies cellulation number impact (plaque number/10
6splenocyte)
From table 9: each group plaque number compares with negative control group plaque number, there was no significant difference (P>0.05).
B: develop immunitypty preparation on the impact of mice serum hemolysin, in table 10:
Table 10 develop immunitypty preparation is on the impact (antibody product) of mice serum hemolysin
From table 10: the antibody product of three groups is significantly higher than negative control antibody product, wherein of the present invention group of effect is optimum, and has synergistic function.
(5) develop immunitypty preparation is on mouse monokaryon--the impact of macrophage function, see 11,12:A: develop immunitypty preparation is on mouse monokaryon--and the impact of macrophage carbonic clearance, in table 11:
Table 11 develop immunitypty preparation is on mouse monokaryon--the impact (phagocytic index) of macrophage carbonic clearance
From table 11: three dosage groups can significantly improve mouse carbonic clearance ability, wherein of the present invention group of effect is optimum, and has synergistic function.
B: develop immunitypty preparation engulfs the impact of chicken red blood cell ability, in table 12 to Turnover of Mouse Peritoneal Macrophages:
The impact of chicken red blood cell phagocytic rate engulfed by table 12 develop immunitypty preparation on Turnover of Mouse Peritoneal Macrophages
From table 12: three groups of phagocytic percentages, phagocytic index more all increase with negative control group phagocytic index, wherein of the present invention group of effect is optimum, and has synergistic function.
(6) develop immunitypty preparation is on the impact of NK cells in mice activity, in table 13:
Table 13 develop immunitypty preparation is on the impact of NK cells in mice activity
From table 13: the NK cytoactive of three groups compares with negative control group NK cytoactive significant difference, wherein of the present invention group of effect is optimum, and has synergistic function.
Above experimental result shows, prebiotic compositions of the present invention has immune increasing action because adding this composition of Glucosamine Sulphate, is specially adapted to weakness of the spleen and the stomach, osteoporosis, need the long-term taking of the crowd of supplement calcium, be also applicable to strengthening children's bone tissue growth, increase immunity of organisms.
Detailed description of the invention:
Further illustrate the present invention by the following examples, but not as limitation of the present invention.
Embodiment 1
Prebiotic compositions, the component containing following weight portion in every 100g:
Preparation method, mixes the component of above-mentioned weight proportion and get final product.
Embodiment 2
Preparation containing prebiotic compositions
Prebiotic compositions, 100g
Auxiliary material, 100g
Above-mentioned raw materials mixes, and granulate, compressing tablet, is prepared into the tablet of 0.5g/ sheet.
Embodiment 3
Preparation containing prebiotic compositions
Prebiotic compositions, 100g
Auxiliary material, 100g
Above-mentioned raw materials mixes, and granulates, in incapsulating, is prepared into the capsule of 0.5g/ capsules.
Embodiment 4
Preparation containing prebiotic compositions
Prebiotic compositions, 100g
The auxiliary materials such as sucrose, 100g
Above-mentioned raw materials mixes, and granulates, packaging, the often packed granule having 5 grams.
Embodiment 5
Preparation containing prebiotic compositions
Prebiotic compositions, 100g
The auxiliary materials such as sucrose, 100g
Above-mentioned raw materials is packed after being prepared into powder mixing, the often packed pulvis having 5 grams.
Embodiment 6
Prebiotic compositions, described composition, the weight proportion of each component is as follows:
Embodiment 7
Prebiotic compositions, described composition, the weight proportion of each component is as follows:
Claims (7)
1. a prebiotic compositions, described composition, the weight proportion of each component is as follows:
2. prebiotic compositions according to claim 1, described composition, the weight proportion of each component is as follows:
3. the preparation method of prebiotic compositions according to claim 1, described method comprises the step each component mixed.
4. the applicable oral preparation made using prebiotic compositions according to claim 1 as active component.
5. preparation according to claim 4 is food or health food.
6. preparation according to claim 5 is granule or pulvis.
7. preparation according to claim 6 is that described granule or pulvis are distributed into bag, 5 grams every bag.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510263942.3A CN104824511A (en) | 2015-05-21 | 2015-05-21 | Prebiotics composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510263942.3A CN104824511A (en) | 2015-05-21 | 2015-05-21 | Prebiotics composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104824511A true CN104824511A (en) | 2015-08-12 |
Family
ID=53803033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510263942.3A Pending CN104824511A (en) | 2015-05-21 | 2015-05-21 | Prebiotics composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104824511A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105876582A (en) * | 2015-08-25 | 2016-08-24 | 成都天美膳营养食品有限公司 | Blood-glucose-reducing and blood-lipid-reducing dietary fiber solid beverage |
| CN107495383A (en) * | 2017-08-14 | 2017-12-22 | 北京市营养源研究所 | One kind relaxes bowel complex prebiotics and preparation method and application |
| CN107927789A (en) * | 2017-12-01 | 2018-04-20 | 刘峰 | A kind of prebiotics food and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101366734A (en) * | 2008-06-18 | 2009-02-18 | 辽宁大生药业有限公司 | Synbiotics medicament composition |
| CN101961346A (en) * | 2010-10-27 | 2011-02-02 | 南通迈特生物工程有限公司 | Self-emulsified prebiotic-containing calcium-iron-zinc soft capsules and preparation method thereof |
| CN102630948A (en) * | 2012-04-19 | 2012-08-15 | 保龄宝生物股份有限公司 | High-fiber sugar-free fruit flavored type compound prebiotics and preparation method thereof |
| CN104256255A (en) * | 2014-10-08 | 2015-01-07 | 保龄宝生物股份有限公司 | Granular functional sugar and preparation method thereof |
| CN104413328A (en) * | 2013-08-22 | 2015-03-18 | 青岛蓝农谷农产品研究开发有限公司 | Immunity enhancing health product |
-
2015
- 2015-05-21 CN CN201510263942.3A patent/CN104824511A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101366734A (en) * | 2008-06-18 | 2009-02-18 | 辽宁大生药业有限公司 | Synbiotics medicament composition |
| CN101961346A (en) * | 2010-10-27 | 2011-02-02 | 南通迈特生物工程有限公司 | Self-emulsified prebiotic-containing calcium-iron-zinc soft capsules and preparation method thereof |
| CN102630948A (en) * | 2012-04-19 | 2012-08-15 | 保龄宝生物股份有限公司 | High-fiber sugar-free fruit flavored type compound prebiotics and preparation method thereof |
| CN104413328A (en) * | 2013-08-22 | 2015-03-18 | 青岛蓝农谷农产品研究开发有限公司 | Immunity enhancing health product |
| CN104256255A (en) * | 2014-10-08 | 2015-01-07 | 保龄宝生物股份有限公司 | Granular functional sugar and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 吴文坚等: "硫酸氨基葡萄糖治疗骨关节炎新进展", 《国外医学.骨科学分册》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105876582A (en) * | 2015-08-25 | 2016-08-24 | 成都天美膳营养食品有限公司 | Blood-glucose-reducing and blood-lipid-reducing dietary fiber solid beverage |
| CN107495383A (en) * | 2017-08-14 | 2017-12-22 | 北京市营养源研究所 | One kind relaxes bowel complex prebiotics and preparation method and application |
| CN107927789A (en) * | 2017-12-01 | 2018-04-20 | 刘峰 | A kind of prebiotics food and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2769462C2 (en) | Synergetic production of butyrate related to complexity of bmo mixture for use in infants or young children for medical purposes | |
| AU2001231746B2 (en) | Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response | |
| JP5498698B2 (en) | New uses of white jellyfish miscellaneous polysaccharides or their extracts | |
| DE602004006133T2 (en) | NEW GALACTOOLIGOSACCHARID COMPOSITION AND MANUFACTURE THEREOF | |
| CN105722515A (en) | Compositions for use in the prevention or treatment of URT infections in infants or young children at risk | |
| CN105722514A (en) | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section | |
| AU2001231746A1 (en) | Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response | |
| CN103284156A (en) | Healthcare product composition and application thereof | |
| CN101934070A (en) | Veterinary antibacterial drug composition containing lysozyme and oligosaccharide and application thereof | |
| CN106820151A (en) | A kind of bivalve compound health composition, preparation method and application | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| CN107427697A (en) | Treatment diarrhoea and the method for promotion intestinal health in non-human animal | |
| JP2816726B2 (en) | Composition for improving intestinal environment | |
| CN107198246A (en) | A kind of health composition and a kind of health care preparation | |
| CN103249421A (en) | Endometriosis prevention and/or improving agent, and food or drink composition containing same | |
| CN104824511A (en) | Prebiotics composition | |
| CN103976359B (en) | Food nutrient fortifying composition and application, health food and preparation method thereof | |
| CN107095308A (en) | A kind of probiotics preparation and its application | |
| CN110313599A (en) | A kind of anti-trioxypurine jelly and preparation method thereof | |
| CN101912407B (en) | Weight-reducing and lipid-lowering composition | |
| US20230065964A1 (en) | Composition for enhancing urolithin production in a human subject | |
| CN108653298A (en) | Monosaccharide composition, pharmaceutical preparation and its application | |
| JPWO2007144943A1 (en) | Immune function enhancing composition | |
| CN105920606A (en) | Compound oral liquid for treating children diarrhea and preparation method thereof | |
| RU2325166C1 (en) | Pharmaceutical formulation of antibiotics and lactulose applied for prevention of enteral disbiosis caused by antibiotic therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150812 |